RepliCel Life Sciences Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was CAD 0.836082 million compared to CAD 0.597994 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.02 a year ago.
For the nine months, net loss was CAD 3.24 million compared to CAD 1.33 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.05 a year ago.